Discovery & Development Europe 2026
.png)
Estrel Congress Centre, Germany
.png?width=470&height=151&name=Formulation%20%26%20Delivery%20Europe%202026%20Updated%20(Light).png "Formulation & Delivery Europe 2026 Updated (Light)")
Day
Solution Provider Presentation
Solution Provider PresentationA Novel OncoLytic Peptide platform - Immunogenic Cell Death initiation for Immune Cell Recruitment
Industry Presentation• Novel Oncolytic Peptide therapies for hard to treat cancers
• Membrane-Lytic Peptides and immunogenic cell death
• Reprogramming the local tumour microenvironment for systemic response
Unlocking Non Traditional Delivery Routes For Small Molecule Therapeutics
Industry Presentation• Why intranasal delivery is compelling for small molecules
• Formulation and device considerations unique to intranasal products
• Development, safety, and translational challenges
Small Molecule Formulations & Dosage Form With Patient Friendly Delivery Considerations
Industry PresentationOligonucleotide Delivery & Utilising sRNA Delivery Methods In Alternative Modalities
KeynoteSolution Provider Presentation
Solution Provider PresentationSeparation Of PS Diastereomers In GalNAc-Conjugated siRNA By IP‑RP, AEX & HILIC
Industry PresentationRegulatory Hurdles For Biologics Delivery & Formulation
Industry PresentationOpportunities And Challenges In Developing And Manufacturing Radiopharmaceuticals
Industry Presentation• Expanding theranostic applications
• Complex manufacturing, isotope supply constraints, and short half-life logistics
• Regulatory hurdles, GMP compliance, and specialised infrastructure requirements
Oral Dosage Form Improvement
Industry PresentationNext-Generation Drug Delivery Devices: Balancing Patient Experience, Safety, And Performance
Panel Discussion• Design innovation & regulatory considerations
• Human factors & adherence
Challenges And Unities For The Delivery Of Biopharmaceuticals
Panel Discussion• Recent technological advancements & platforms
• Predicting future successes
Overcoming Scientific And Technological Challenges Of Formulating Oral GLP-1 Therapies
Panel DiscussionThis panel will explore the scientific and technological challenges of formulating oral GLP-1 therapies, including absorption enhancement, stability, bioavailability, and patient-centric design
• Formulation strategies
• Emerging delivery platforms
• Blood Brain Barrier challenges
• Translational hurdles
• Future directions shaping next-generation oral peptide therapeutics
Exploring Alternative Routes Of Administration For Biologics Beyond IV
Roundtable DiscussionLiposomal Formulation Development: Safety And Efficacy Assessment
Industry PresentationCharacterising Chemical And Physical Properties
Industry PresentationpH Gradient Driven Loading of Anticancer drug into Niosomes with Bromocresol Green as a Visual Indicator
Industry Presentation- Studying the effect of different co-surfactants on stabilising the niosomal membrane.
- Investigating the influence of niosomes' compositions on formation of a pH gradient.
- Visualisation of pH gradients via pH indicator bromocresol green (BCG) as a novel encapsulated model molecule to visually investigate the ability of niosomes to entrap drugs through active loading.
- Application of the most optimised BCG niosomal formulation to encapsulate a therapeutic anticancer drug molecule via pH gradient active loading.
NAMS Approaches For Ethical Drug Development
Roundtable DiscussionsiRNA Therapies Utilising Lipid Nanoparticles
Industry PresentationOvercoming Challenges Of Clinical Formulations For PROTAC
Industry PresentationCell & Gene Delivery Platforms & Technologies
Industry PresentationFormulating Next-Gen Biotherapeutics: Strategies To Enhance Stability, Quality, And Scalability
Panel Discussion• Stabilising complex modalities
• Evaluating non-traditional formulation strategies — including lyophilisation, co-formulation, microencapsulation, or amorphous systems
Ophthalmology Formulation For Biologics Delivery
Industry PresentationFrom Molecule To Mouth: The Innovation Behind Oral GLP‑1
Industry Presentation• Key scientific breakthroughs enabling oral GLP‑1 (enhancers, formulation, devices)
• Translational challenges and clinical proof-of-concept
• Next-generation strategies for improving efficacy and scalability
Solution Provider Presentation
Solution Provider PresentationEx-Vivo Platform Development For Topical Treatments
Industry PresentationSolution Provider Presentation
Solution Provider PresentationSolution Provider Presentation
Solution Provider PresentationSolution Provider Presentation
Solution Provider PresentationAccelerating Formulation Modelling With AI And Novel Technologies
Industry PresentationmRNA Design With Lipid Nanoparticles & AI Assistance
Industry PresentationRegulatory Landscape Of Smart Devices
Industry PresentationLarge Molecules Formulation For Inhaled Therapies
Industry PresentationThe Future Of Biologics Delivery: High-Concentration Subcutaneous Administration
Panel Discussion• Latest scientific and engineering advances enabling high-dose, low-viscosity SC delivery of monoclonal antibodies and other biologics
• Aligning delivery platform decisions with long-term competitiveness, patient access, and global commercialisation strategies
Peptide Delivery Reimagined: Navigating Challenges And Seizing Opportunities For Oral Delivery
Industry Presentation• Challenges of GLP-1 formulations ensuring stability, permeability, solubility enhancement and overall effectiveness of the final product
• Key formulation strategy to enhance oral administration of peptides
Innovations In Biologics Formulation And Processes
Industry PresentationPrediction Of Longterm Stability Of Monoclonal Antibodies Using Innovative Biophysical And Data Science Tools
Industry Presentation• Advanced biophysical characterisation to understand degradation pathways and stability risks
• Integration of data science and predictive modelling to forecast long-term stability
• Accelerating developability assessment and formulation decision-making through in-silico insights
The Nitrosamines Formulation Hurdle
Industry Presentation• Crystal defects have been shown as the primary cause of nitrosamine formation in ranitidine hydrochloride
• Recrystallisation of ranitidine hydrochloride can essentially stop the formation of nitrosamines on storage by eliminating crystal defects
• This technology can be used in conjunction with traditional nitrosamine-reducing approaches to further mitigate nitrosamine formation for all crystalline drugs
Improving Biopharmaceuticals With Drug Product Platforms And Smart Technologies
Industry PresentationStrategies For High-Concentration Subcutaneous Antibody Therapeutics
Industry Presentation• Challenges and opportunities in developing high-dose antibody formulations suitable for subcutaneous administration
• Overview of innovative formulation and delivery approaches for high-concentration biologics
• Key considerations related to manufacturability, scalability, and regulatory expectations for next-generation antibody therapeutics
Overcoming Challenges In Large Molecule Drug Formulation
Industry PresentationSolution Provider Presentation
Solution Provider PresentationSolution Provider Presentation
Solution Provider PresentationSolution Provider Presentation
Solution Provider PresentationSolution Provider Presentation
Solution Provider PresentationImprovement Of Oral Bioavailability Of Acylated Peptides
Industry PresentationSolution Provider Presentation
Solution Provider PresentationSolution Provider Presentation
Solution Provider PresentationSolution Provider Presentation
Solution Provider PresentationParticle Engineering To Drive Sustainability
Industry Presentation
Announcement of Young Scientist Poster Presentation Awards by ELRIG & Start of Wine Tasting Activities
Morning Break & Refreshments
Morning Break & Refreshments
Wine Tasting & Dinner
Experience Berlin like never before with our VR Formula One racing tour, followed by an evening of drinks, wine tasting, and invite-only exclusive dinner. Connect with peers, unwind, and enjoy the city’s sights in a relaxed, social setting.
AI-Driven Drug Discovery Platforms: Real Value, Real Limits
Panel Discussion• The AI platform landscape:
o Biology-first vs chemistry-driven vs lab-integrated approaches
o Where differentiation is real & where it is overstated
• Where AI is delivering value today
• How pharma is engaging with AI platforms in practice
• Scalability, integration, and long-term ROI
Digitalisation Including Generative AI – Case Study From Sanofi
Industry PresentationThe Real Impact Of AI On Drug Discovery Workflows
Panel Discussion• AI in:
o Drug design
o High throughput screening
o Hit finding
• Productivity gains, limits, and evolution of data/models
• Industry case studies on generative AI: what worked, why, and data sources
• Measuring success and identifying next steps for improvement
The Rise And Fall Of SARM1 Base-Exchange Inhibitors
Industry PresentationStart Up Presentation
Solution Provider PresentationAI Case Study
Industry PresentationSolution Provider Presentation
Solution Provider PresentationCandidate Optimisation With Physiologically-Based Pharmacokinetic Modelling
Industry PresentationTranslation From Preclinical To Clinical At The DZNE
Industry PresentationLeveraging Affinity Screening For Hit Discovery
Industry Presentation
Lunch Break
Afternoon Break & Refreshments
End of Event
Lunch Break
Including Scheduled Demos in the AI & Digitisation Zone by AI Platform Companies
Iambic’s AI/ML & HTE Platform – A Case Study
Industry PresentationImproving The Efficiency And Effectiveness By Implementing FAIR Guiding Principles For Pharmaceutical R&D Data
Industry PresentationDrug Discovery a:head: A Human Brain Organoid Screening Platform
Industry PresentationChemical Space Generation, Exploration & Visualisation
Industry PresentationFutures Of Small Molecule Discovery
Industry PresentationModulating Sleep As An Entry Point To Treating Neurodegenerative Disorders
Industry PresentationMultitarget Ligands for Multifactorial Diseases
Industry PresentationCancer, neurological disease (such as Parkinson's and Alzheimer’s ), and microbial illness are multifactorial diseases difficult to treat with drugs that act on a single target. During the last few years, two strategies have emerged as valuable tools in the scientist's continuous fight against multifactorial diseases. One strategy, the conventional one, consists in combinations of different drugs that interact with different single targets. The second strategy consist in the Multiple Targeting Drugs or Ligands (MTD) approach, where a single chemical entity interacts with two or more distinct biological targets related to a disease. The MTD drugs/ligands are usually classified in Hybrid Drugs (HD) and Chimeric Drugs (CD). As a result of the MTD approach will result new drug candidates with improved pharmacodynamic, pharmacokinetic, and toxicologic properties, improved patient compliance, etc. On the other hand, nitrogen heterocycles derivatives are invaluable scaffolds in drug design and medicinal chemistry, possessing a large variety of biological activities such as anticancer, antimicrobial (antibacterial, antifungal, anti-TB, antiplasmodial, etc.), antiviral, antihypertensive, anticoagulants, antidepressant, anti-Alzheimer’s, etc.).
In continuation of our continuous efforts in the field of nitrogen heterocyclic derivatives, we present herein some recent results obtained by our group in the field of multitarget azaheterocycles ligands for multifactorial diseases, anticancer, antimicrobial and anti-Alzheimer’s. The presentation will be focused on the design, synthesis, and biological activity of some hybrid and chimeric nitrogen heterocyclic derivatives, including (but not only) derivatives with imidazole, benzimidazole, pyridines, quinolines, phenanthrolines, pyridazines, etc. Some of the obtained compounds are promising leading drug candidates.
Smarter, Faster, Leaner: Digitalising Drug Product Development
Panel Discussion• Integrating PAT, digital twins & AI for continuous workflows
• Real-world impact: productivity gains and decision-making power
• Balancing innovation with regulatory compliance
Is The Neurometabolic Approach The Missing Link In Neurodegenerative Disease Treatment?
Industry PresentationTarget Discovery With Functional Genomics – From Novel Targets To Patient Stratification
Industry PresentationDrugging The Undruggables: TPD Approaches
Industry PresentationMoving Toward A Definition For Neuroinflammation
Panel Discussion• Exploring what we really mean by neuroinflammation
• Highlighting key cellular and immune features involved in brain inflammation
• Considering how clearer definitions could guide future research and treatment
Solution Provider Presentation
Solution Provider PresentationNext-Gen Payloads To Address ADC Resistance
Industry PresentationAI Case Study
Industry PresentationDesigning For Impact – Moving Beyond Inhibitors
KeynoteInnovative High-Throughput TSA & qPCR Platforms: New Opportunities In Drug Discovery
Industry PresentationHigh-throughput technologies provide a robust foundation for the discovery of novel lead structures. At Bayer, we have developed advanced platforms for high-throughput quantitative PCR (qPCR) and thermal shift assays (TSA). Case studies demonstrate how these technologies empowered successful hit identification. In addition, strategies for designing diverse and effective compound libraries are discussed, highlighting their critical role in successful screening campaigns.
High Throughput Biomarker Analysis
Industry PresentationDeveloping GAL3 Degraders For The Treatment Of Alzheimer’s Disease
Industry PresentationHit To Lead: How Are You Optimising Your Screening Strategy In 2026?
Panel Discussion• Evolving library design: full-deck vs focused screens
• Automation, DELs, and new assay formats
• Modalities and target classes: tailoring optimisation strategies
DEL Screening For Small Molecule Hit-To-Lead
Industry PresentationNIDB-3101: A Third Generation Anti-Tau Biparatopic Antibody Designed For Enhanced Therapeutic Efficacy In AD
Industry Presentation• NIDB-3101 binds two distinct Tau epitopes and has Fc mutations for enhanced half-life
• NIDB-3101 binds a larger variety of Tau entities from AD brain tissue than benchmark Abs and robustly inhibits AD brain-derived seeds induced intracellular Tau aggregation
• The combination of sub-nanomolar affinity and cellular activity together with enhanced half-life leads to a modelled lower human efficacious dose than benchmark
Designing And Implementing Digitalisation & AI Strategies In The Lab
Industry PresentationSolution Provider Presentation
Solution Provider PresentationAdvanced Screening Approaches
Industry PresentationClosed-Door Panel Discussion: Partnerships, Platforms Or Acquisitions: What Is The Winning Model For Brain Health Innovation?
Panel Discussion• Pharma-biotech-academia collaboration models that actually work
• When to partner vs acquire vs build internally
• Data-sharing in a competitive landscape
• Public-private partnerships in Europe: success stories & failures
• Regional differences – US vs EU
o Scaling in Europe
Generative Molecular Design – Advancing From Hits To Leads
Industry PresentationFocused Innovation Through Partnerships
Industry Presentation• Introduction to Lundbeck External Research & Innovation
• Recent examples of building partnerships with Lundbeck
Tackling Challenges With mRNA Delivery
Panel Discussion• Innovative mRNA formulations and delivery approaches
• Improving selectivity and efficiency of delivery
• Utilising data driven approaches to cover come delivery challenges
Neuroscience At Servier – Case Studies From The Clinic
Industry PresentationNovel Hit Identification Strategies – Part 2
Industry PresentationModeling Ternary Complexes With Molecular Glues: Making Sense Of A Sticky Situation
Solution Provider PresentationUsing Experimental Medicine To Accelerate Target Selection For Parkinson’s Disease Psychosis
Industry Presentation• Theoretical position for intracellular kinase modulation
• Experimental modelling to validate target/drug probe
• Initial data in patients
Fostering Cross-Sector Partnerships To Accelerate Drug Discovery
Roundtable Discussion• The future of partnering & what to prioritise
• Bringing together AI & data cross-functionally to drive drug discovery
Assays Around The Clock: Autonomous Robotics In Merck's Early Drug Discovery
Industry PresentationAutonomous Mobile Robots (AMRs) transform research by automating routine tasks and extending operational hours to nights and weekends. We are implementing our first AMR, integrating liquid handlers, incubators, and readers for fully automating any microtiter plate assay in our Lab of the Future. This pioneering solution will boost productivity and enhance research outcome
Preclinical Discovery for Novel ADCs
Industry PresentationIntegrating Multi-Omics Data To Understand Disease Mechanisms
Industry PresentationAdvancing Paediatric Genetic Medicines
Industry PresentationPreclinical Characterisation Of IPN60300, A First-In-Class Antibody-Drug Conjugate For Cancer Therapy
Industry PresentationUtilising Chemical Biology For Target Identification & Validation
Industry PresentationDEL Screening For Membrane Proteins
Industry PresentationTo Be Confirmed
Industry PresentationSolution Provider Presentation
Solution Provider PresentationAI In Drug Design
Industry PresentationTarget 2035 – Accelerating Drug Discovery Through Partnerships
Industry PresentationData-Driven Drug Development
Industry PresentationThe Power Of Precision Radiation: Radiopharmaceuticals Transforming Targeted Oncology
Industry PresentationStrategies for Building a Forward-Looking, Value-Driven IP Portfolio
Roundtable Discussion• Tailoring IP portfolio architecture to therapeutic modality (from small molecules to complex biologics)
• The IP paradox in AI-driven drug discovery (inventorship, confidentiality, ownership)
A Novel Platform For Identifying New Therapeutics
Industry PresentationThe Future Of Protein Degradation: Beyond PROTACs & Molecular Glues
Panel Discussion• Expanding target scope
• Resistance mechanisms
• Clinical pipeline readiness
• New effectors for TPD
Generative AI For Real World Evidence
Industry PresentationMultimodal Screening Strategy For Discovery Of Novel Cereblon-Directing Molecular Glue Degraders And Neosubstrates
Industry PresentationCombining In Vitro & Mathematical Modelling To Predict Efficacy
Industry PresentationFrom Data Silos to Connected Knowledge: Accelerating Tech Transfers Through End‑to‑End Digitalisation
Industry PresentationConfounding Factors In Targeted Degradation Of Short-Lived Proteins
Industry PresentationOrganoids And Advanced Vitro Models: Improving Translation And Replacing The Use Of Animals
Industry PresentationLab Digitalisation & AI
Industry PresentationSolution Provider Presentation
Solution Provider PresentationDiscovery of FKBP12-Based Competitive Molecular Glues
Industry PresentationHow Can We Leverage All Pre-Clinical Information To Inform The First In Human Trial?
Panel Discussion• PK, safety & biomarker data
• Clinical relevance of models
• Leveraging literature vs datasets
• Personalised medicine
• Regulatory considerations
Solution Provider Presentation
Solution Provider PresentationInnovative Functional Groups In Medicinal Chemistry To Accelerate Drug Discovery
Industry Presentation- Medicinal chemists are challenged to discover drugs for increasingly difficult targets, while reducing the time towards clinical candidate selection
- The more functional groups we can utilize in compound design, the higher our chances might be to succeed
- This presentation will highlight emerging functional groups in medicinal chemistry such as the N-trifluoromethyl group and demonstrate how they can be strategically applied to optimize for example potency, metabolic stability, and oral absorption
- Expect to leave this session with some inspiring new chemical features and data supporting their application to optimize the properties of compound series, generate IP, and accelerate drug discovery
Where Smart Capital Meets Science: Investing In The Next Wave Of Innovation & AI In Drug Discovery
Panel Discussion• How investors evaluate emerging drug discovery technologies
o AI in drug discovery
• What drives funding decisions in a shifting biotech market
• Where capital is flowing next
• What drives founding decisions?
Is Neuroscience The Next Oncology? Industry Trends In Therapeutic Focus
Panel Discussion• Key drivers behind renewed pharma and biotech interest (e.g., Alzheimer’s approvals, novel mechanisms, better biomarkers)
• Market dynamics
Solution Provider Presentation
Solution Provider PresentationFrom Discovery To Development: Making Partnerships Work
Industry PresentationChemical Probes As Drivers Of Phenotypic Screening And Discovery
Industry PresentationSolution Provider Presentation
Solution Provider PresentationSolution Provider Presentation
Solution Provider PresentationTo Be Confirmed
Industry PresentationTBC
FAIR Data Management In Labs Of The Future
Industry PresentationMulti-Omics Technologies For Novel Target Discovery
Industry PresentationNon Degrading Molecular Glues - Insights on Molecular Interactions for Inhibiting PPIs and GTPases
Industry Presentation- Non-Degrading molecular glues inhibit protein targets through formation of a ternary complex. In this talk, our development of macrocyclic molecular glues that recruits FKBP12 will be discussed in context of inhibiting PPIs and other target classes.
- The structural basis for inhibiting PPIs will be shown through X-Ray structural data of ternary complexes with disruption of the TRADD-TRAF2 PPI being detailed.
- Learning from structural based drug design using ternary crystal structures will be presented.
Advanced ADC Discovery Platforms
Industry PresentationMaking Automation Smarter At AstraZeneca
Industry PresentationAdvancing Industry & Academic Partnerships To Accelerate Drug Discovery
Panel DiscussionAdventures Tn Precision Medicine For Cancer: 25 Years After The Genome Sequence
Keynote• Oncology leads the way in genome-based medicine with estimates of at least 90 FDA approvals requiring biomarkers for optimal patient selection – almost half of all drugs authorized since 1998
• In discovery, ‘Drugging the Cancer Genome’ is being further enabled by technologies such as CRISPR, chemical probes, structure/fragment-based design, degraders (PROTACs and molecular glues), immune-targeting and AI/machine learning approaches
• In clinical development, use of the ‘Pharmacological Audit Trail’ framework is being enhanced by cheaper next generation sequencing, liquid biopsy, and innovative PK/PD modelling
Brain Health: A Call For Global Action & Unity
KeynoteNeuroimmune Targeting: From iPSC Models To Data-Driven Insights
Panel Discussion• Integration of iPSC-derived cell models to explore neuroimmune mechanisms and validate emerging targets
• Translational value and challenges of modulating neuroinflammatory targets like TREM2 and RIPK1
• Sex specific differences
The Landmark Consortium
Industry PresentationFrom Proximity Induction To Degradation: Advancing Molecular Degraders At Merck Healthcare
Industry PresentationTargeted protein degradation presents a significant opportunity to tackle previously undruggable targets by utilizing the cell's proteasomal system to eliminate disease-causing proteins.
At Merck Healthcare KGaA, we have established specialized workstreams for bifunctional PROTACs and molecular glue degraders.
Examples of our hit identification from PPI, Del and hit characterization will be presented, highlighting our tailored assay suite to optimize these modalities in our drug discovery pipeline.
Pushing The Boundaries Of Target Discovery In 2026 & Beyond – New Technologies, Approaches, Industry Directions
Panel Discussion• The evolution of modalities
• When to pursue small molecules, ADCs, protein degraders, RNA modalities, or multi-modal approaches
The Automation & AI Landscape In 2026
KeynoteCovalent Protein Kinase Inhibitors Targeting Cysteine And Beyond
Industry PresentationThe Toxicity Challenge: What’s Holding Back ADC Innovation?
Panel Discussion• Antibody engineering to improve toxicity
• Balancing potency vs tolerability in payload design
• Will novel formats improve the toxicity profile?
Leveraging iPSC Models To Understand Neuroinflammatory Targets
Industry PresentationHuman Translatable Cellular Models & Pre-Clinical Research
Industry PresentationA Human Stem Cell Derived Micorglia Single Cell Atlas - State Transitions In Response To Challenge
Industry PresentationGeneration of single cell RNA seq altas of iPSC microglia from 20 prodromal AD donors
Microglial states and their transition in response to different challenges
Molecular pathways induced by challenge
Closing The Gap: Patient-Derived Microtumours (PDMs) In Precision Oncology And Preclinical Drug Development
Industry PresentationPatient-derived microtumours (PDMs), isolated from surgical tumour resections, preserve the native tumour microenvironment, including structural heterogeneity and immune interactions. This platform allows for physiologically relevant, in vitro evaluation of lead candidates, such as advanced therapy medicinal products (ATMPs) and immunotherapies, while supporting the identification of personalised, patient-specific cancer treatment strategies.
An Advanced ADC Platform & Design Principles
Industry PresentationRethinking The Pre-Clinical Modelling
Industry PresentationUtilising AI In Hit Identification
Industry PresentationBuilding A Truly Connected, Automated Discovery Lab
Panel Discussion• Bridging silos between devices, data platforms & teams
• Achieving interoperability: tech, teams, and standards
• Scaling automation from proof-of-concept to full lab adoption
To Be Confirmed
Industry PresentationSolution Provider Presentation
Solution Provider PresentationTo Be Confirmed
Industry PresentationTBC
Solution Provider Presentation
Solution Provider PresentationSolution Provider Presentation
Solution Provider PresentationAI Case Study
Industry PresentationSolution Provider Presentation
Solution Provider PresentationSolution Provider Presentation
Solution Provider PresentationSolution Provider Presentation
Solution Provider PresentationSolution Provider Presentation
Solution Provider PresentationSolution Provider Presentation
Solution Provider PresentationTo Be Confirmed
Industry PresentationTBC
Solution Provider Presentation
Solution Provider PresentationLeading The Future: Women Driving Innovation In Drug Discovery & Development
Panel Discussion• Career journeys and lessons from senior women in pharma, biotech, and academia
• Navigating leadership challenges, mentoring, and fostering inclusive R&D teams
• Breaking silos: cross-functional collaboration to accelerate drug development
• Inspiring the next generation of women scientists and leaders
Enabling Challenging Targets: Development of AS-MS and Integration with Other Screening Technologies
Industry PresentationTBC
Start Up Presentation
Solution Provider PresentationSolution Provider Presentation
Solution Provider PresentationStart Up Presentation
Solution Provider PresentationSolution Provider Presentation
Solution Provider PresentationSolution Provider Presentation
Solution Provider PresentationTo Be Confirmed
Industry PresentationSolution Provider Presentation
Solution Provider PresentationSolution Provider Presentation
Solution Provider PresentationTBC
Industry PresentationEstablishing Secure Digital Infrastructure
Industry PresentationNo sessions found matching your filters.